Skip to content
HowShorted

Dianthus Therapeutics, Inc. short interest in 2024

In 2024, Dianthus Therapeutics, Inc.'s disclosed short interest ran from 0.33% of shares outstanding on 12 Jan 2024 to 20.28% on 31 Dec 2024, a change of +19.95 percentage points. The year's high was 20.28% on 31 Dec 2024 and its low 0.33% on 12 Jan 2024, averaging 11.20% across 22 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 38.14 days on 13 Sep 2024. Full history: Dianthus Therapeutics, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Dianthus Therapeutics, Inc. in 2024

2024 in figures

Start of year
0.33% (12 Jan 2024)
End of year
20.28% (31 Dec 2024)
Change
+19.95 pp
High
20.28% (31 Dec 2024)
Low
0.33% (12 Jan 2024)
Average
11.20%
Highest days to cover
38.14 (13 Sep 2024)
SEC filings marked
9

Every report in 2024

Dianthus Therapeutics, Inc. short interest in 2024
SettlementShort interestDays to coverFilings since previous
12 Jan 20240.33%1.21results (8-K)
31 Jan 20240.64%1.01
15 Mar 20243.63%7.31
28 Mar 20244.74%6.7410-K filed, results (8-K)
15 Apr 20246.50%11.65
30 Apr 20247.32%12.71
15 May 20247.10%18.4310-Q filed, results (8-K)
31 May 20247.08%17.52
14 Jun 20246.70%10.36
28 Jun 20247.98%3.06
15 Jul 202411.39%15.30
31 Jul 202412.49%17.36
15 Aug 202413.83%24.0310-Q filed, results (8-K)
30 Aug 202414.67%29.27
13 Sep 202414.75%38.14
30 Sep 202416.94%19.68
15 Oct 202416.10%16.19
31 Oct 202417.36%34.39
15 Nov 202418.39%13.1210-Q filed, results (8-K)
29 Nov 202418.97%25.49
13 Dec 202419.13%28.95
31 Dec 202420.28%31.09

See also: Dianthus Therapeutics, Inc.'s full history · most shorted US stocks of 2024 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.